Metabolic Acidosis Clinical Trials

Find Metabolic Acidosis Clinical Trials Near You

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis

Status: Recruiting
Location: See all (28) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Have provided written informed consent prior to participation in the study.

• Male or female participants 18 years of age or older.

• Diagnosed with CKD (eGFR \< 60 mL/min/1.73m2) and not expected to require renal replacement therapy (dialysis or kidney transplant) throughout the duration of the study.

• Within 6 months prior to screening have at least two SBC between 12 and 20 mmol/L, inclusive. If only one historical SBC is available, a second SBC may be drawn on screening visit S1 and analyzed by the local laboratory.

• Within screening period have two central laboratory SBC (at least 24 hours apart and more than 4 hours after food) between 12 and 21 mmol/L, inclusive.

• Willing to keep food consumption similar to baseline throughout the entire study.

• If taking oral alkali therapy, dose has been stable for at least 28 days prior to the start of screening and is expected to remain stable throughout the study.

• Women who are of childbearing potential must have a negative pregnancy test and agree to abstinence or to use contraception.

Locations
United States
California
Study Site
RECRUITING
Chula Vista
Study Site
RECRUITING
Los Angeles
Study Site
RECRUITING
Sacramento
Study Site
RECRUITING
San Diego
Colorado
Study Site
RECRUITING
Aurora
Delaware
Study Site
RECRUITING
Newark
Florida
Study Site
RECRUITING
Edgewater
Study Site
RECRUITING
Margate
Study Site
RECRUITING
Miami Springs
Study Site
RECRUITING
Orlando
Georgia
Study Site
TERMINATED
Augusta
Idaho
Study Site
RECRUITING
Boise
Study Site
RECRUITING
Chubbuck
Study Site
RECRUITING
Idaho Falls
Illinois
Study Site
RECRUITING
Chicago
Indiana
Study Site
RECRUITING
Indianapolis
Kentucky
Study Site
RECRUITING
Louisville
Louisiana
Study Site
RECRUITING
New Orleans
Michigan
Study Site
RECRUITING
Detroit
Study Site
RECRUITING
Pontiac
Missouri
Study Site
RECRUITING
Kansas City
North Carolina
Study Site
RECRUITING
Winston-salem
New York
Study Site
RECRUITING
Fresh Meadows
Study Site
RECRUITING
New York
Texas
Study Site
RECRUITING
Fort Worth
Study Site
RECRUITING
Houston
Study Site
RECRUITING
San Antonio
Study Site
RECRUITING
Van Vleck
Contact Information
Primary
Ayla Rasmussen
arasmussen@renibus.com
443-569-9228
Time Frame
Start Date: 2026-01-13
Estimated Completion Date: 2027-06
Participants
Target number of participants: 150
Treatments
Experimental: Veverimer
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Renibus Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials